Know what your
deal is worth
Stop guessing on upfronts, milestones, and royalties. Benchmark your deal against 1,900+ real transactions in seconds.
See Your Deal Terms Instantly
Select parameters below — benchmarks update in real time
Free to use. No account required.
How It Works
Get deal term estimates in three simple steps
Enter Asset Details
Select therapeutic area, development phase, modality, indication, and other key parameters for your asset.
Analyze Market Data
Our algorithm processes your inputs against publicly available deal benchmarks and market data.
Get Full Deal Intelligence
Receive instant estimates, rNPV analysis, Monte Carlo simulations, comparable deals, AI deal memos, partner matching, company profiles, and negotiation playbooks.
Built for Life Sciences Professionals
Whether you're a biotech founder, BD executive, or investor, get instant benchmarks for your deals
Deal Benchmarking
Instant benchmarks from 1,900+ real deals across 12 therapeutic areas. Upfront payments, milestones, royalties, and comparable deal matching.
Financial Modeling
Risk-adjusted NPV (rNPV) analysis and Monte Carlo simulation with 10,000 iterations. Model probability-weighted deal outcomes and scenario ranges.
Market Pulse
Weekly market intelligence with benchmark sparklines, deal flow trends, competitive landscape analysis, and market size & epidemiology data.
Company Intelligence
Deep profiles on 850+ pharma and biotech companies with deal history, pipeline tracking, patent cliff timelines, and intelligent partner matching.
Deal Toolkit
AI deal memos, negotiation playbooks, sensitivity analysis, scenario comparison, outreach email generation, and 16-page branded PDF reports.
Enterprise-Grade Platform
GDPR-compliant data handling, authenticated APIs, rate-limited endpoints, WCAG-accessible interface, and daily SEC EDGAR + FTC pre-merger data ingestion.
Every Role, One Platform
From early-stage founders to boardroom advisors, Ambrosia gives you the data edge in every deal conversation
For Founders
- Know your asset's market value with rNPV analysis and Monte Carlo simulation
- Present data-backed terms with institutional deal memos and negotiation playbooks
- Run sensitivity analysis and model scenario ranges before entering the room
For BD Teams
- Screen opportunities with AI partner matching and company intelligence profiles
- Generate board-ready PDF reports, AI deal memos, and negotiation playbooks
- Track deal flow with Market Pulse dashboard and watchlist alerts
For Boards & Investors
- Validate deal terms with rNPV models and benchmarks from 2,500+ deals across 850+ companies
- Review Monte Carlo probability distributions and scenario comparisons
- Monitor market trends with Market Pulse intelligence and deal alerts
For M&A Advisors
- Accelerate due diligence with rNPV models, comparable deals, and company profiles
- Build data-driven negotiation strategies with AI playbooks and outreach templates
- Export branded PDF and Excel reports with full financial modeling for clients
Manual Analysis vs Ambrosia
How institutional deal benchmarking should work
Time to analyze
Data coverage
Financial modeling
Comparable deals
Partner intelligence
Cost
Find Your Ideal Licensing Partner
Our AI matches your asset profile against 850+ pharma and biotech companies to find the best strategic fit
Beyond Benchmarks
Full financial modeling and market intelligence tools that turn data into deal strategy
rNPV & Monte Carlo Simulation
Risk-adjusted net present value analysis with 10,000-iteration Monte Carlo simulation. Model probability-weighted deal outcomes across development phases, regulatory milestones, and commercial scenarios.
Market Pulse Intelligence
Real-time market intelligence dashboard with benchmark sparklines, deal flow trends by modality, competitive landscape analysis, and market size & epidemiology data across therapeutic areas.
Company Profiles & Pipeline
Deep profiles on 850+ pharma and biotech companies with historical deal flow, active pipeline tracking from ClinicalTrials.gov, patent cliff timelines, and strategic fit scoring.
Advanced Deal Intelligence
Institutional-grade deal memos, negotiation playbooks with counterparty-specific tactics, outreach email templates, and 16-page branded PDF reports — all customized to your specific asset and market position.
Built for Life Sciences Deal-Making
Benchmarks derived from 1,900+ publicly disclosed licensing deals sourced from SEC filings, press releases, and FTC pre-merger filings. Updated daily with new transactions.
Choose Your Plan
One report for a single deal, or unlimited access for your entire pipeline.
Deal Intelligence Report
20-page PDF + Excel for a single deal. Comparable transactions, partner matching, negotiation playbook.
- rNPV with index drug validation
- Multi-buyer valuation
- Monte Carlo + VaR/CVaR
- Negotiation playbook
Pro — Unlimited Access
Unlimited calculations, all 14 engines, partner matching, and export. For teams running multiple deals.
- Everything in Report, unlimited
- Buyer-specific valuation (3 partners)
- Pharma Intent Score (10-factor)
- Tornado + compound scenarios
Deal Intelligence Guides
In-depth resources for BD teams, deal committees, and licensing professionals — backed by data from 1,900+ transactions.
Biopharma Licensing Benchmarks 2026
Upfront, milestone, and royalty benchmarks by phase, modality, and TA
MethodologyrNPV Biotech Valuation Guide
Phase transition probabilities, cash flow modeling, and Monte Carlo enhancement
BenchmarksPharma Royalty Rate Benchmarks
Royalty rates by phase and modality with negotiation strategies
TutorialDeal Calculator Guide
14 engines, 12 therapeutic areas, 23+ modalities — how to use the platform
StrategyDeal Structure Guide
Upfront, milestone, and royalty allocation by deal type and stage
ValuationHow to Value a Biotech Deal
Step-by-step using comparables, rNPV, and Monte Carlo simulation
Ambrosia Ventures
A boutique strategy and M&A advisory firm specializing in life sciences. We help biotech companies, pharmaceutical corporate development teams, and investors navigate licensing deals, M&A transactions, and strategic partnerships.